<DOC>
	<DOC>NCT00380718</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy and toxicity of pemetrexed dosing that is tailored to individual patient tolerance in patients with advanced non-small cell lung cancer (NSCLC).</brief_summary>
	<brief_title>Chemotherapy for Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologic or cytologic diagnosis nonsmall cell lung cancer (NSCLC) (Stage IIIB or IV) Patients' NSCLC must have progressed following one chemotherapy regimen for palliative therapy with or without subsequent targeted biological therapy Disease status must be that of measureable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 Concurrent administration of any other tumor therapy Pregnancy or breast feeding Serious concomitant disorders Inability or unwillingness to take folic acid or vitamin B12 supplementation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>